The protein tyrosine phosphatase, non-receptor type 11 (PTPN11) gene encodes SHP-2, a phosphatase involved in many signaling pathways, with a key role in development and hematopoiesis. Somatic PTPN11 mutations were found with variable prevalences in pediatric leukemia, most frequently associated with juvenile myelomonocytic leukemia (JMML). 1, 2 In vitro and in vivo studies, mainly in a myeloid context, demonstrated a crucial involvement of PTPN11 mutations in the hyperactivation of the RAS/ERK pathway. 3 The oligoclonality of transgene integration sites, and the long latency before overt leukemia in mice transduced with mutant PTPN11, 3 suggested that additional molecular lesions are needed to cooperate with PTPN11 mutations in leukemogenesis. This observation is in line with the 'two hit model' proposed by Greaves 4 for B-cell precursor childhood acute lymphoblastic leukemia (ALL), in which an initiating alteration, often occurring prenatally, gives rise to a preleukemic clone, which eventually becomes fully malignant by subsequent acquisition of other molecular alterations.
We previously documented that somatically acquired PTPN11 mutations occur in approximately 10% of B-cell precursor childhood ALL. 2 Molecular profiling indicated that PTPN11 mutations were largely mutually exclusive with NRAS and KRAS mutations, suggesting a perturbing role of PTPN11 mutations on signal flow through RAS in ALL as well. In childhood ALL, high hyperdiploidy (450 chromosomes) is the most frequent cytogenetic aberration, accounting for 30% of the cases. 5 Although several lines of evidence support the view that hyperdiploidy is an early leukemogenic event, frequently occurring prenatally, 6 the long latency before overt leukemia strongly indicates that, also for hyperdiploidy, additional alterations in the leukemic clone are required. 6 Although a higher prevalence of mutations in genes coding for transducers with a role in RAS signaling in high hyperdiploid childhood ALL cases has been reported, 7, 8 the order of the events before overt disease in PTPN11-mutated ALL has not been addressed.
With this aim, we genotyped the available DNA from relapsed ALL cases with a PTPN11 mutation at disease presentation, and performed single-nucleotide polymorphism (SNP) mapping analysis in PTPN11-mutated cases at diagnosis to identify the presence of additional genetic alterations.
In our previous screening, we identified 23 PTPN11 mutationpositive ALL patients. 2 Among these cases, four patients relapsed, and biological samples of three patients were available to be genotipically characterized ( Figure 1 ). All patients studied were enrolled in the AIEOP-BFM ALL 2000 clinical trial, approved by the Institute Review Board, which includes the usage of left over material for research purposes. Diagnosis was established according to the standard morphologic, cytochemical and immunologic criteria. For all the following analyses, mononuclear cells were separated from bone marrow aspirates by Ficoll gradient, and genomic DNA was extracted. PCR amplification of PTPN11 exons 3 and 13 was performed as previously described. 2 Amplified PCR products were subsequently screened for mutations by denaturing high-performance liquid chromatography, and direct sequencing was performed on variant denaturing high-performance liquid chromatography elution profiles. The samples were also screened by PCR for immunoglobulin (Ig) and T-cell receptor (TCR) gene rearrangements. PCR products were further examined by gel homoheteroduplex analysis to discriminate between monoclonal and polyclonal lymphoid cell populations, and clonal PCR products were then sequenced.
Blasts from patient no. 638 showed no major differences in immunophenotype (CD19 þ , CD10 þ , cyIgM À ) and hyperdiploidy between diagnosis and relapse; the PTPN11 T-to-C transition at position 1504 observed at diagnosis was also present at relapse. Consistently, Ig/TCR rearrangements identified at diagnosis were stable at relapse, although an additional Vg11-Jg2.3 and two DH2-JH6 rearrangements occurred.
In patient no. 588, two Ig/TCR rearrangements were in common between diagnosis and relapse, while a VgI-Jg1.3 rearrangement was present only at diagnosis and an additional Vd2-Dd3 rearrangement was observed at relapse. Similarly, at disease relapse, blasts maintained a CD19
phenotype, even though they did not express CD22 that, together with trisomy 10, was present only at diagnosis. Sequencing of PTPN11 exon 3 demonstrated that the G-to-A transition at position 226 was no longer present at disease relapse. A similar finding was documented for patient no. 944, whose leukemic cells at relapse did not exhibit the C-to-T change at position 215 documented at diagnosis. Of note, a sub-population of blasts at disease relapse were found to carry a different PTPN11 mutation, A(227)T. Ig/TCR diagnostic rearrangements were present in the relapse sample, demonstrating the origin from the same precursor cell, although two additional Dd2-Dd3 rearrangements indicated a clonal evolution. At diagnosis, blasts were hyperdiploid and showed (among other alterations) disomy for chromosome 10, trisomy for chromosome 14 and quadrisomy for chromosome 21. Karyotype, fluorescence in situ hybridization and SNP mapping data were not available for this case at disease relapse. Quantitative PCR on genomic DNA by using the Universal Probe Master system (Roche Applied Science, Monza, Italy), testing HCLS as a target gene (on chromosome 21) and MBL-2 as a reference gene (on chromosome 10), confirmed the presence of quadrisomy 21 in blasts at relapse (data not shown). Consistently, the retention of three IgH rearrangements and the presence of three TCRdelta rearrangements (both on chromosome 14) strongly suggested that trisomy 14 was also present at relapse, supporting the idea that leukemic cells at disease relapse were characterized by a hyperdiploid karyotype. Figure 2 summarizes the natural history of the disease in these patients, based on the Ig/TCR pattern and PTPN11 mutation status at diagnosis and relapse. In conclusion, we showed that in 
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Letters to the Editor childhood ALL the clone harboring a PTPN11 mutation appears to be unstable at relapse.
Moreover, an additional mutational screening of a cohort of 158 patients with B-cell precursor ALL allowed the identification of heterozygous missense PTPN11 mutations in 9 subjects (Supplementary Table 1 ). Of note, in seven of the nine patients with a PTPN11 mutation, denaturing high-performance liquid chromatography profiles and sequencing traces suggested that the gene lesion represented only a sub-population of blasts. This last feature is in line with the recent findings by Case et al., 9 who found the same pattern for mutations affecting genes coding for transducers with a role in RAS signaling at disease presentation.
Overall, these findings strongly suggest that, differently from what is observed in JMML, PTPN11 mutations in ALL have a secondary, cooperative role in the leukemogenic process, rather than an initiator one. In addition, given the sensitivity to extinction of clones carrying PTPN11 mutations, SHP-2 is unlikely to be a good target for therapy in ALL. In fact, inhibiting SHP-2 will not eliminate clones without a PTPN11 mutation, which more often tend to relapse.
To identify lesions potentially cooperating with PTPN11 mutations in ALL, we performed SNP mapping arrays, to look for whole-genome aberrancies not visible by conventional cytogenetic techniques.
Of the 23 PTPN11 mutation-positive cases previously identified, 2 genomic DNA at diagnosis was available for 21 patients (of which 20 also had paired remissions) to be analyzed by SNP mapping arrays. GeneChip Human Mapping 100K Array (Affymetrix, Santa Clara, CA, USA), and CNAG v2.0 software (Genome Laboratory, Tokyo University, Tokyo, Japan; http:// www.genome.umin.jp/CNAGtop2.html) were used for hybridization and data analysis (Supplementary Table 2 ). Copy number alterations (CNA) and uniparental disomies were detected in a large fraction of patients, confirming results of previous studies documenting the recurrence of these lesions in childhood ALL. 10 None of these lesions had high recurrency or was specifically associated with PTPN11 mutation-positive cases, although the number of samples analyzed might be too small to detect any differences (Supplementary Table 3 ). The mean frequency of CNA per patient was 7.7 for amplifications (s.d. 3.9, range 0-13, including entire chromosomal gains) and 1.4 for deletions (s.d. 2.2, range 0-8).
Patient no. 1012 carried amplification of chromosome 12q24, which includes the PTPN11 gene. This alteration has been recently found in a Noonan syndrome-like patient without mutations in the PTPN11 gene, 11 and in two patients with acute myeloblastic leukemia. 12 Of note, increased expression of SHP2 has been shown to potentially contribute to leukemogenesis. 13 In this patient, the amplification was associated with a PTPN11 mutation. Therefore, this aberrancy is expected to have an enhancing effect on signaling dysregulation promoted by the SHP2 mutant.
In conclusion, SNP mapping characterization detected many CNA and some uniparental disomies. The frequency of the most known aberrations, including deletions of chromosome 12, deletions of chromosome 9 (involving PAX5, CDKN2A/B or Letters to the Editor MLLT3), amplifications of chromosome 1q or chromosome 9 uniparental disomies was in line with data reported by others, 10 therefore not representing specific features. As a complementary approach to further explore the impact of PTPN11 mutations in ALL, we also performed an explorative gene expression profiling analysis of childhood ALL cases, which did not reveal any PTPN11 mutation-specific feature (see Supplementary analyses, Supplementary Tables 4, 5, Figures 1 and 2) .
Importantly, among PTPN11 mutated cases, the proportion of hyperdiploid karyotype detected by SNP mapping arrays was significantly higher compared with the expected prevalence of 44%, as detected by conventional cytogenetic techniques (Po0.001). 5 In particular, we observed a strong difference for the high hyperdiploid subtype (450 chromosomes; 76.2%, confidence interval: 52.8-91.8%), compared with the expected 32% (Po0.0001). 5 Among hyperdiploids, chromosomes 4-6-10-14-17-18-21-X were more frequently affected by trisomies-tetrasomies, showing no difference from the typical hyperdiploid ALL pattern.
The identification of a significant association of PTPN11 mutations with the high hyperdiploid karyotype, previously described for FLT3, NRAS and KRAS mutations, 7, 8 confirm and extend our previous observation in childhood ALL. 2 Increasing evidence supports the view that hyperdiploidy is an early event in leukemogenesis, which frequently occurs at a prenatal level. 6 The cooperative role of PTPN11 mutations and their association with hyperdiploidy suggest an intriguing pathogenetic model, in which a high hyperdiploid preleukemic clone becomes fully malignant by the acquisition of a PTPN11 mutation (and, potentially, other alterations). Patient no. 944 is an example supporting this model: both diagnosis and relapse originate from the same preleukemic clone (as shown by Ig/TCR rearrangements), and retain hyperdiploidy, but two different PTPN11 mutations occur at diagnosis and relapse. The occurrence of a different mutation affecting PTPN11 further highlights the relevance of lesions of this gene in the malignant progression of high hyperdiploid childhood ALL.
In conclusion, the evolution of leukemia in the cases presented here showed that PTPN11 mutations are secondary, cooperative events associated with a high hyperdiploid karyotype. Further studies are needed to assess the effects of PTPN11 mutants in lymphoid cell models, especially in terms of hyperactivation of signaling pathways and phenotypic effects.
